The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.
Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.
Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.
The Multicentric Italian Lung Detection study findings indicate that extending lung cancer screening beyond 5 years boosts the survival benefits associated with early disease detection.
The NILE study has shown the noninferiority of cell-free DNA analysis, so-called liquid biopsy, to the standard of care for identifying targetable biomarkers in individuals with treatment-naïve metastatic non-small-cell lung cancer.